Login to Your Account

Apogenix Lands $12.5M for CD95 Ligand Inhibitor

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, January 11, 2012
Apogenix AG took in €7.5 million (US$9.6 million) in new investments, plus a further €2.3 million in government funding, to continue clinical development of its lead molecule, APG101, and to fund associated biomarker research.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription